Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

NHCMG selects athenahealth as preferred HIT vendor

The New Haven Community Medical Group, or NHCMG, has selected athenahealth, Inc., a provider of cloud-based services for electronic health records, or EHRs, practice management and care coordination, as one of its preferred health information technology, or HIT, vendors.

Published By MarketLine
30 Jul 2014
NewsWire
NewsWire

Mylan wins motion for temporary restraining order against Apotex

Mylan Inc., a generic and specialty pharmaceutical company, has won motion for a temporary restraining order against Apotex Inc. and Apotex Corporation, a provider of generic drugs, in litigation relating to Paroxetine CR, the authorized generic of GlaxoSmithKline's Paxil CR from the US District Court for the District of New Jersey.

Published By MarketLine
30 Jul 2014
NewsWire
NewsWire

Sartorius Q2 net profit decreases

Sartorius Group, a provider of laboratory and pharmaceutical equipment, has reported that net profit attributable to shareholders of the company for the second quarter ended June 30, 2014 was E11.4 million, or E0.67 per ordinary share, compared to E14.3 million, or E0.84 per ordinary share, for the same quarter ended June 30, 2013.

Published By MarketLine
29 Jul 2014
NewsWire
NewsWire

Krka H1 profit increases

Krka, d. d., Novo mesto., a generic pharmaceutical company, has reported a profit attributable to the equity holders of the parent of E106.61 million, or E3.25 per share, for the six months ended June 30, 2014, compared to E100.34 million, or E3.03 per share, for the same period ended June 30, 2013.

Published By MarketLine
29 Jul 2014
NewsWire
NewsWire

VirtualScopics names president and CEO

VirtualScopics, Inc., a provider of clinical trial imaging solutions, has named Eric Converse as president and CEO.

Published By MarketLine
28 Jul 2014
NewsWire
NewsWire

rEVO Biologics enrolls first patient in Phase III preeclampsia clinical trial

rEVO Biologics, Inc., a subsidiary of LFB Biotechnologies, has announced the enrollment of the first patient in its Phase III clinical trial of ATryn, for the treatment of preeclampsia during the 24th to 28th week of pregnancy, or early onset preeclampsia.

Published By MarketLine
28 Jul 2014
NewsWire
NewsWire

Magellan Health appoints new director

Magellan Health, Inc., a healthcare management company, has appointed Kay Coles James to the company's board of directors.

Published By MarketLine
28 Jul 2014
NewsWire
NewsWire

Mead Johnson reports lower Q2 net earnings, provides annual outlook

Mead Johnson Nutrition Company, a developer of pediatric nutrition products, has reported that net earnings attributable to shareholders for the second quarter ended June 30, 2014 were $171.4 million, or $0.84 per diluted share, compared to $172 million, or $0.84 per diluted share, for the same quarter ended June 30, 2013. For 2014, the company expects non-GAAP EPS to be in the range of $3.65 to $3.72.

Published By MarketLine
28 Jul 2014
NewsWire
NewsWire

Christie, Elekta and Philips to develop MRI-guided radiation therapy for cancer

Elekta, a provider of clinical solutions for treating cancer and brain disorders, and Royal Philips, a medical technology company, have announced that The Christie NHS Foundation Trust, a specialist cancer center, has joined their research consortium to develop the integrated magnetic resonance imaging, or MRI, guided radiation therapy system for cancer treatment.

Published By MarketLine
28 Jul 2014
NewsWire
NewsWire

Wee-Cig launches new type of pancake coil atomizer

Wee-Cig International Corporation has launched a new type of pancake coil atomizer for micro dried herb pens.

Published By MarketLine
28 Jul 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.